MTHFR 677C/T基因多态性与培美曲塞对晚期肺腺癌患者疗效的关系

Association of MTHFR 677C/T gene polymorphism with therapeutic effect of pemetrexed in advanced lung adenocarcinoma

目的探索亚甲基四氢叶酸还原酶(methylenetetrahydrofolate reductase,MTHFR)677C/T基因多态性在预测培美曲塞治疗晚期肺腺癌疗效中的作用。方法 39例初治晚期肺腺癌患者入组并行培美曲塞/顺铂方案化疗,37例患者按要求完成治疗并进行随访。通过Taqman MGB探针实时荧光定量PCR方法检测患者MTHFR677C/T位点的基因多态性,分析基因多态性与化疗客观缓解率(response rate,RR)和无进展生存时间(progression-free survival,PFS)的关系。结果 MTHFR 677C/T基因频率:CC 40.5%(15/37),CT 43.2%(16/37),TT 16.2%(6/37),MTHFR CC、CT和TT基因型客观缓解率之间差异无统计学意义(26.7%vs 31.3%vs 50.0%,P=0.582)。CC基因型与CT或TT基因型之间PFS差异无统计学意义(4.7月vs 6.9月,P=0.499)。结论 MTHFR 677C/T多态性可能与晚期肺腺癌培美曲塞化疗疗效无相关性。

Objective To investigate the association of methylenetetrahydrofolate reductase（MTHFR） gene polymorphism with the therapeutic effect of pemetrexed in advanced lung adenocarcinoma.Methods Thirty-nine patients with advanced lung adenocarcinoma were enrolled in this study and treated with pemetrexed plus cisplatin.Thirty-seven finished the treatment and were followed up.MTHFR 677C/T gene polymorphism was determined in blood samples from the patients by quantitative real-time PCR using Taqman MGB probes.The relationship between gene polymorphism,response rate and progression-free survival was analyzed.Results The percentages of CC,CT and TT genotypes in MTHFR（rs1801133） were 40.5%,43.2% and 16.2%.The response rates of patients with genotype CC,CT and TT were not statistically different（26.7% vs 31.3% vs 50.0%,P=0.582）.No significant difference in progression-free survival was observed between patients with genotype CC and CT or TT（4.7 m vs 6.9 m,P=0.499）.Conclusion There is no association between MTHFR 677C/T gene polymorphism and response in patients with advanced lung adenocarcinoma receiving pemetrexed/cisplatin chemotherapy.